copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
A Study of Amivantamab Alone or in Addition to Other . . . - Janssen The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent metastatic head and neck cancer The study will also confirm the recommended Phase 2 combination dose (RP2CD) for
Home | Global Trial Finder What You Can Expect To Happen In A Clinical Trial Clinical trials are rarely the same They can last from weeks to years, study different doses of a medication, or even compare multiple medications at once While the details change, all trials are structured in a similar way Typically, there are four main parts of a trial, with each part serving a different purpose
TREMFYA® - cloud. e. janssen. com TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light) TREMFYA® is a prescription medicine used to treat adults with active psoriatic arthritis
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid . . . The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose [s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R R) acute myeloid leukemia (AML) or R R higher-risk type of myelodysplastic neoplasms (type of cancer of the blood and bone marrow, which does not respond to
A Phase 1 2 Study of Bleximenib in Participants With Acute Leukemia The purpose of this study is to determine the recommended Phase 2 dose (s) (RP2D [s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion) The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D
Nipocalimab in Moderate to Severe Sjogrens Disease (DAFFODIL) This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD